Utah Medical Products (UTMD) Peer Comparison

$68.08

$1.28 (1.91%)

As on 30-Oct-2026 16:00EST

Market cap

$194 Mln

Revenue (TTM)

$35 Mln

P/E Ratio

20.4

P/B Ratio

1.8

Div. Yield

0.5 %

Edit

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
Market cap ($ Mln)	194	12,682	10,876	11,234	14,302
Revenue ($ Mln)	35	1,560	6,636	806	690
Net Profit ($ Mln)	10.64	157.02	337.20	-11.80	-169.80
Net Margin (%)	30.48	10.06	5.08	-1.47	-24.60
RoE (%)	8.74	10.27	5.90	-0.56	-24.46
Price to Earnings	20.38	79.11	32.10	--	--
Price-To-Book	1.76	8.19	1.94	5.37	20.01

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
Operating Revenue	34.92	1,560.33	6,635.60	805.61	690.33
Cost of Revenue	14.77	499.55	4,539.20	394.34	130.29
Gross Profit	22.00	942.44	2,139.40	347.62	393.22
Operating Expenses	9.69	871.54	1,593.70	392.34	623.34
Operating Profit (EBIT)	10.45	189.25	502.70	18.93	-63.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	12.98	207.82	315.50	8.23	-174.52
Provision for Tax	2.33	50.81	-21.70	20.03	-4.72
Profit after Tax (Net Income)	10.64	157.02	337.20	-11.80	-169.80
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	47.34	0.00	0.00	0.00

Liabilities ($ Mln)

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
Shareholder's Funds	123.28	1,583.51	5,835.90	2,091.74	717.27
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	0.48	207.78	4,425.10	708.99	135.53
Current Liabilities	4.74	233.81	1,369.00	125.69	126.73
Total Liabilities	122.54	1,826.52	11,794.70	2,949.70	893.49

Assets ($ Mln)

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
Non-Current Assets	27.87	648.47	9,037.40	1,684.42	399.88
Current Assets	100.63	1,376.63	2,592.60	1,241.98	579.65
Total Assets	122.54	1,826.52	11,794.70	2,949.70	893.49
Total Debt*	0.18	209.39	3,683.80	692.24	101.98
Net Current Assets	0.00	0.00	1,223.60	0.00	452.92

Cashflow ($ Mln)

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
Cash From Operating Activities	14.69	238.66	623.80	117.42	-46.34
Cash Flow from Investing Activities	-0.37	-404.59	-130.50	-298.47	-77.61
Cash from Financing Activities	-12.34	26.53	-409.40	-15.21	11.89
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
ROCE (%)	9.51	11.76	-5.43	1.79	-22.53
ROE (%)	8.74	10.27	5.90	-0.56	-24.46
ROA (%)	6.01	5.91	2.57	-0.33	-15.48
EBIT Margin (%)	37.16	13.40	7.39	4.20	-24.51
Net Margin (%)	30.48	10.06	5.08	-1.47	-24.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
Revenue Growth (%)	-9.62	16.98	0.92	13.80	46.94
EBIT Growth (%)	-6.51	11.72	106.97	29.47	-106.70
Net Profit Growth (%)	-8.42	-4.27	510.22	-779.17	-93.80
EPS Growth (%)	-5.51	-4.95	507.22	-910.66	-90.00
Book Value Growth (%)	5.13	15.61	4.89	0.35	-12.58

Valuation Ratios

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
Price / Earnings	15.86	68.93	-14.68	189.42	-34.59
Price / Book Value	1.76	8.19	1.94	5.37	20.01
Dividend Yield (%)	0.46	0.00	0.00	0.00	0.00
EV/EBITDA	7.28	53.91	15.90	88.63	-114.22
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
Debt to Equity	0.00	0.00	0.63	0.00	0.00
Short term debt to equity ratio	0.00	0.01	0.01	0.01	0.00
Current Ratio	21.23	5.89	1.89	9.88	4.57
Quick Ratio	19.00	3.92	1.27	8.43	4.09
Interest Coverage	--	165.16	2.81	1.24	-35.23

Operating Efficiency Ratios

	Utah Medical Products (UTMD)	Penumbra (PEN)	Avantor (AVTR)	Repligen (RGEN)	Glaukos Corp (GKOS)
Debtors to sales (%)	11.34	12.51	16.92	18.77	21.73
Asset Turnover	0.20	0.59	0.51	0.22	0.63
Receivable days	36.11	46.54	58.79	72.41	60.95
Inventory Days	185.15	331.92	64.13	146.53	193.84
Payable days	16.07	26.16	58.13	29.05	60.19
Cash Conversion Cycle	205.18	352.30	64.79	189.88	194.60

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly